GeneDx prelim Q4 revenue >$57M, exome/genome rev +63% YoY; cash burn -51% YoY

GeneDx Holdings Corp.

2023-FY EPS reported -$7.23 revenue$202,566,000

Q4 continuing ops revenue >$57M (+24% YoY); exome/genome revenue >$38M (+63% YoY).
Exome/genome test results 15,663 in Q4 (+99% YoY), now 27% of total test volume.
Cash and equivalents $131M as of Dec 31, 2023.
Q4 cash burn $33M, down 51% YoY and 21% sequentially; reiterates 2025 profitability path.
Full year 2023 continuing ops revenue expected at least $193M; exceeded revised guidance.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeneDx Holdings Corp. reported full year 2023 results: revenue at least $193 million. Guidance reaffirmed.

Period: full year 2023
Revenue: at least $193 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Management expects GeneDx to report: • revenues of at least $193 million for full year 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeneDx Holdings Corp. reported fourth quarter of 2023 results: revenue at least $57 million. Guidance reaffirmed.

Period: fourth quarter of 2023
Revenue: at least $57 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Financial Results (Unaudited) Continuing Operations Results: 1 Management expects GeneDx to report: • revenues of at least $193 million for full year 2023 • revenues of at least $57 million in the fourth quarter, an increase of 24% year-over-year and 13% sequentially; • exome and genome test revenues of at least $38 million in the fourth quarter, an increase of 63%

View on SEC.gov

Browse all earnings releases →

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001818331-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.